Another Eylea rival struggles in phase 2, this time fielded by Ribomic
Another Eylea rival struggles in phase 2, this time fielded [...]
After ‘masterful’ development of Keytruda, Merck’s CMO follows Roger Perlmutter to Eikon
After ‘masterful’ development of Keytruda, Merck’s CMO follows Roger Perlmutter [...]
2seventy bio’s honeymoon phase is over as job cuts hit 6% of staff
2seventy bio’s honeymoon phase is over as job cuts hit [...]
ORIC walks away from lead cancer resistance program after lackluster phase 1b data
ORIC walks away from lead cancer resistance program after lackluster [...]
Aligos hacks off 2nd hep B med since January after ‘unexpected’ reaction in 4 patients
Aligos hacks off 2nd hep B med since January after [...]
Moderna trains its mRNA tech on the common cold and a triple whammy against 3 respiratory diseases
Moderna trains its mRNA tech on the common cold and [...]
Chasing Big Pharma trio, Bavarian Nordic sells Chinese rights to RSV vaccine candidate in $225M deal
Chasing Big Pharma trio, Bavarian Nordic sells Chinese rights to [...]
Immunogen’s phase 3 ADC survival data spook investors, sending stock down ahead of FDA filing
Immunogen’s phase 3 ADC survival data spook investors, sending stock [...]
Bristol Myers lands $1.1B biobucks oncology pact with Volastra, a biotech with phones ‘ringing off the hook’
Bristol Myers lands $1.1B biobucks oncology pact with Volastra, a [...]
Summit says path forward for failed C. difficile drug is likely through partnerships
Summit says path forward for failed C. difficile drug is [...]